# A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

> **NCT02202759** · PHASE2 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Adenocarcinoma of the Stomach
- Gastroesophageal Junction Expressing Guanylyl Cyclase C

## Interventions

- **DRUG:** MLN0264

## Key facts

- **NCT ID:** NCT02202759
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08-04
- **Primary completion:** 2016-01-15
- **Final completion:** 2016-01-15
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Business Decision, No Safety or Efficacy Concerns
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02202759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02202759, "A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02202759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*